0001176309 false 0001176309 2023-07-13 2023-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 13, 2023

 
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

 

delaware

001-35813

98-0376008

(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

 

1185 Avenue of the Americas, Third Floor, New York, New York

10036

(Address of Principal Executive Offices) (Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.012   ORMP  

The Nasdaq Capital Market,

Tel Aviv Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

On July 13, 2023, Oramed Pharmaceuticals Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders. The final voting results at the 2023 Annual Meeting of Stockholders are set forth below.

 

Proposal No. 1 — Re-election of Directors.

 

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

 

Director Name For     Against     Abstain     Broker Non-Votes
                             
Dr. Miriam Kidron   9,157,849       173,775       74,353       7,707,173
                             
Nadav Kidron   9,182,326       168,225       55,426       7,707,173
                             
Dr. Arie Mayer   8,920,370       438,226       47,381       7,707,173
                             
Yadin Rozov   8,949,343       411,701       44,933       7,707,173
                             
Leonard Sank   8,696,513       654,931       54,533       7,707,173
                             
Benjamin Shapiro   9,239,878       120,124       45,975       7,707,173

 

 

Proposal No. 2 — Ratification of Independent Registered Public Accounting Firm for the 2023 Fiscal Year.

 

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2023 fiscal year. The votes were as follows:

 

For     Against     Abstain     Broker Non-Votes  
                             
  16,991,347       50,052       71,751       -  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  ORAMED PHARMACEUTICALS INC.
   
  By:  /s/ Nadav Kidron
 

Name:

Title:

Nadav Kidron
President and CEO

 

July 13, 2023

 

 

v3.23.2
Cover
Jul. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 13, 2023
Entity File Number 001-35813
Entity Registrant Name ORAMED PHARMACEUTICALS INC.
Entity Central Index Key 0001176309
Entity Tax Identification Number 98-0376008
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1185 Avenue of the Americas
Entity Address, Address Line Two Third Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
City Area Code 844
Local Phone Number 967-2633
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.012
Trading Symbol ORMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Oramed Pharmaceuticals Charts.
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Oramed Pharmaceuticals Charts.